This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Open AccessReview
The Therapeutic Potential of the Specific Intestinal Microbiome (SIM) Diet on Metabolic Diseases
by
Natural H. S. Chu
Natural H. S. Chu 1,*
,
Elaine Chow
Elaine Chow 1
and
Juliana C. N. Chan
Juliana C. N. Chan 1,2,3
1
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China
2
Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China
3
Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China
*
Author to whom correspondence should be addressed.
Submission received: 11 June 2024
/
Revised: 2 July 2024
/
Accepted: 4 July 2024
/
Published: 4 July 2024
Simple Summary
Prebiotics, essential for humans and our gut microbiome, maintain the ecosystem’s homeostasis in a mutual relationship with the host and microbiome. As a gut microbiome modulator, poorly absorbed or indigestible carbohydrates interact with the gut microbiome, and its metabolites promote immune health. However, there is limited discussion of a habitual diet in metabolic diseases. Exploring the intricate crosstalk between dietary prebiotics and the specific intestinal microbiome (SIM) is intriguing to gain deeper insights into their therapeutic implications.
Abstract
Exploring the intricate crosstalk between dietary prebiotics and the specific intestinal microbiome (SIM) is intriguing in explaining the mechanisms of current successful dietary interventions, including the Mediterranean diet and high-fiber diet. This knowledge forms a robust basis for develo** a new natural food therapy. The SIM diet can be measured and evaluated to establish a reliable basis for the management of metabolic diseases, such as diabetes, metabolic (dysfunction)-associated fatty liver disease (MAFLD), obesity, and metabolic cardiovascular disease. This review aims to delve into the existing body of research to shed light on the promising developments of possible dietary prebiotics in this field and explore the implications for clinical practice. The exciting part is the crosstalk of diet, microbiota, and gut–organ interactions facilitated by producing short-chain fatty acids, bile acids, and subsequent metabolite production. These metabolic-related microorganisms include Butyricicoccus, Akkermansia, and Phascolarctobacterium. The SIM diet, rather than supplementation, holds the promise of significant health consequences via the prolonged reaction with the gut microbiome. Most importantly, the literature consistently reports no adverse effects, providing a strong foundation for the safety of this dietary therapy.
Share and Cite
MDPI and ACS Style
Chu, N.H.S.; Chow, E.; Chan, J.C.N.
The Therapeutic Potential of the Specific Intestinal Microbiome (SIM) Diet on Metabolic Diseases. Biology 2024, 13, 498.
https://doi.org/10.3390/biology13070498
AMA Style
Chu NHS, Chow E, Chan JCN.
The Therapeutic Potential of the Specific Intestinal Microbiome (SIM) Diet on Metabolic Diseases. Biology. 2024; 13(7):498.
https://doi.org/10.3390/biology13070498
Chicago/Turabian Style
Chu, Natural H. S., Elaine Chow, and Juliana C. N. Chan.
2024. "The Therapeutic Potential of the Specific Intestinal Microbiome (SIM) Diet on Metabolic Diseases" Biology 13, no. 7: 498.
https://doi.org/10.3390/biology13070498
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details
here.
Article Metrics
Article Access Statistics
For more information on the journal statistics, click
here.
Multiple requests from the same IP address are counted as one view.